Immunotherapy plus chemo before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding the immunotherapy drug Adebrelimab to standard chemotherapy before surgery for people with stage II or III non-small cell lung cancer (the most common type) that can be removed. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your general health is good enough for daily activities (ECOG score 0 or 1).
- You have been diagnosed with stage II, IIIA, or specific stage IIIB non-small cell lung cancer that a surgeon believes can be completely removed.
- Your tumor tests positive for PD-L1 (a protein) at a level of 1% or higher.
- You have not had any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- Your major organs (like liver, kidneys, and blood counts) work well enough based on blood tests.
- If you can become pregnant or get someone pregnant, you agree to use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests combining tumor ablation with the immunotherapy drug tislelizumab and chemotherapy before surgery for people with stage II–IIIB non-small cell lung cancer. The goal is to see if this combination helps remove the cancer more effectively.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests adding the immunotherapy drug Adebrelimab to chemotherapy before surgery for people with a type of lung cancer that has certain gene changes. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy, with or without another drug (bevacizumab), given before surgery for people with a certain type of lung cancer. The goal is to see if this combination helps shrink the tumor and makes surgery more effective.
This trial tests whether adding new immunotherapy drugs (adebrelimab or retlirafusp alfa plus recaticimab) to standard chemotherapy before lung surgery can help people with resectable non-small cell lung cancer. The goal is to see if this combination improves outcomes for patients whose tumors can be surgically removed.
Hear when a new Adebrelimab (SHR-1316) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.